Top-10 Biotech Companies - Market Outlook, 2008-2023

Table of Contents

1. Executive Summary

2. Introduction to Biotechnology

• 2.1 Background to Biotech Drugs
  • 2.1.1 Commonly-Used Terminology
  • 2.1.2 Summary of Recombinant DNA Technology
  • 2.1.3 Classes of Biotech Drugs
• 2.2 Biotech Drugs are Gaining Increasing Importance
  • 2.2.1 Biopharmaceuticals are Versatile Agents

3. The World Biotech Market Analysis & Forecast 2008 & 2023

• 3.1 World Biotech Market Expanding Rapidly
• 3.2 Biotech Market Revenues Grew Significantly in 2007
• 3.3 Biotech Market Revenues Forecast 2008-2023
• 3.4 The World Biotech Market is Dominated by North America
• 3.5 Big Pharma Generates Strong Biotech Drug Revenues in 2007
• 3.6 Amgen Records Largest Sales in the Global Biotech Industry in 2007

4. Market Drivers and Restraints in the Global Biotech Market

• 4.1 SWOT Analysis for the Biotech Market
• 4.2 The Principal Drivers in the Biotech Market
• 4.3 The Principal Restraints in the Biotech Market
• 4.4 The Benefits of Biotechnology-Based Products
• 4.5 Biotech Industry Market Capitalisation Gains Momentum
• 4.6 Landmark Biotech Financing in 2007
• 4.7 Healthcare Biotech Venture Capitalist Deals in 2007
• 4.8 Healthcare Biotech VC Fund Investments
• 4.9 Healthcare Biotech IPOs Funds in 2007
• 4.10 New Technology Platforms in Biotech R&D
  • 4.10.1 The Application of Genomic Technology in R&D
  • 4.10.2 Leading Genomics Companies Benefit Through Lucrative Deals with Biotech and Big Pharma
  • 4.10.3 The Application of Proteomics in Drug Discovery Widens
• 4.11 Pharmacogenomics is Crucial to Biotech Revenue Prospects
  • 4.11.1 Pharmacogenomics Holds Potential Benefits
  • 4.11.2 Biomarkers Add to Biotech Technology
• 4.12 US-Style Advance Technology Platform (ATP)
• 4.13 Collaborative Deals That Foster Genomic Applications
• 4.14 Rapidly Expanding Biotech Market Has Marked Challenges Ahead
• 4.15 Increasing Use of Pharmacoeconomic Evaluations is Having an Impact on Revenues of Biotech Medicines
• 4.16 Biotech Companies Must Improve Safety Profile of Drugs
• 4.17 Lack of Adequate Reimbursement Will Impede Potential Growth of the Biotech Market
• 4.18 Potential Growth in Biogenerics (Biosimilars) Market Will Hamper Revenues of Branded Biotech Drugs
• 4.19 EU Leads the Way in Biogenerics Market
• 4.20 The US Awaits New Biogenerics Regulatory Framework
• 4.21 US Congressional Budget Office (CBO) Estimates Biogenerics Will Help Reduce Drug Bills in the Long-Term
• 4.22 Biogenerics Manufacturers Will Face Several Hurdles Despite Lucrative Prospects
• 4.23 European Drug Regulation Framework Promises Increasing Entry of Biogenerics
• 4.24 European Medicines Agency (EMEA) Amends its Biogeneric Regulation
• 4.25 The Future of Healthcare Biotech looks Promising

5. Top-10 Biotech Companies Forecast & Analyses 2008-2023

• 5.1 Top-10 Biotech Companies Revenue Trends Looking Forward

6. Amgen

• 6.1 Key Therapeutic Areas
  • 6.1.1 Cancer
  • 6.1.2 Inflammation
  • 6.1.3 Neurology
  • 6 1.4 Metabolic Disorders
  • 6.1.5 Haematology
• 6.2 Amgen Key Financials
• 6.3 Amgen Revenue Forecast 2008-2023
• 6.4 Amgen' s Leading Drugs
  • 6.4.1 Amgen' s Leading Drug Sales, 2007
• 6.5 Amgen' s Geographical Sales
• 6.6 Amgen' s Top-Three Drugs - Sales Forecasts 2008-2013
• 6.7 Amgen' s Phase III Pipeline

7. Genentech

• 7.1 Key Therapeutic Areas
• 7.2 Genentech Key Financials
• 7.3 Genentech Revenue Forecast 2008-2023
• 7.4 Genentech' s Leading Drugs
• 7.5 Genentech' s Geographical Sales
• 7.6 Genentech' s Top-Three Drugs - Sales Forecasts 2008-2013
• 7.7 Genentech' s Phase III Pipeline

8. UCB

• 8.1 Key Therapeutic Areas
• 8.2 UCB Key Financials
• 8.3 UCB Revenue Forecast 2008-2023
• 8.4 UCB' s Leading Drugs
  • 8.4.1 UCB' s Leading Drugs Sales, 2007
• 8.5 UCB' s Geographical Sales
• 8.6 UCB' s Top-Three Drugs - Sales Forecasts 2008-2013
• 8.7 UCB' s Phase III Pipeline

9. Gilead Sciences

• 9.1 Key Therapeutic Areas
• 9.2 Gilead Sciences Key Financials
• 9.3 Gilead Sciences Revenue Forecast 2008-2023
• 9.4 Gilead Sciences' Leading Drugs
• 9.5 Gilead Sciences Geographic Sales
• 9.6 Gilead Sciences' Top-Three Drugs - Sales Forecasts 2008-2013
• 9.7 Gilead Sciences' Phase III Pipeline

10. Genzyme

• 10.1 Key Therapeutic Areas
• 10.2 Genzyme Key Financials
• 10.3 Genzyme Revenue Forecast 2008-2023
• 10.4 Genzyme' s Leading Drugs
• 10.5 Genzyme' s Geographical Sales
• 10.6 Genzyme' s Top-Three Drugs - Total Sales Forecasts 2008-2013
• 10.7 Genzyme' s Phase III Pipeline

11. Biogen Idec

• 11.1 Key Therapeutic Areas
• 11.2 Biogen Idec Key Financials
• 11.3 Biogen Idec Revenue Forecast 2008-2023
• 11.4 Biogen Idec' s Leading Drugs
• 11.5 Biogen Idec' s Geographical Sales
• 11.6 Biogen Idec' s Top-Two Drugs - Sales Forecasts 2008-2013
• 11.7 Biogen Idec' s Phase III Pipeline

12. CSL

• 12.1 Key Therapeutic Areas
• 12.2 CSL Key Financials
• 12.3 CSL Revenue Forecast 2008-2023
• 12.4 CSL' s Leading Drugs
• 12.5 CSL' s Geographical Sales
• 12.6 CSL' s Top-Three Drugs - Sales Forecasts 2008-2013
• 12.7 CSL' s Phase III Pipeline

13. Cephalon

• 13.1 Key Therapeutic Areas
• 13.2 Cephalon Key Financials
• 13.3 Cephalon' s Revenue Forecast 2008-2023
• 13.4 Cephalon' s Leading Drugs
• 13.5 Cephalon' s Geographical Sales
• 13.6 Cephalon' s Top -Three Drugs - Sales Forecasts 2008-2013
• 13.7 Cephalon' s Phase III Pipeline

14. Celgene

• 14.1 Key Therapeutic Areas
• 14.2 Celgene Key Financials
• 14.3 Celgene Revenue Forecast 2008-2023
• 14.4 Celgene' s Leading Drugs
• 14.5 Celgene' s Geographical Sales
• 14.6 Celgene' s Top-Three Drugs - Sales Forecasts 2008-2013
• 14.7 Celgene' s Phase III Pipeline

15. Actelion

• 15.1 Key Therapeutic Areas
• 15.2 Actelion Key Financials
• 15.3 Actelion Revenue Forecast 2008-2023
• 15.4 Actelion' s Leading Drugs
• 15.5 Actelion' s Geographical Sales
• 15.6 Actelion' s Top-Three Drugs - Sales Forecasts 2008-2013
• 15.7 Actelion' s Phase III Pipeline

16. Conclusions

• 16.1 Biopharmaceutical Treatment Options Expand Significantly over Past Two Decades
• 16.2 Biotech Industry Market Capitalisation Increases
• 16.3 Biotech Market Generated Significant Revenues in 2007
• 16.4 Overall Global Biotech Sales Prospects During the Forecast Period
• 16.5 Prospects for the Top-10 Biotech Companies
• 16.6 Big Pharma' s Presence in the Biotech Arena
• 16.7 Potential Growth in the Biogenerics Market
• 16.8 The US Awaits Consolidation of Biogenerics Regulatory Framework
• 16.9 Prospects for the Healthcare Biotech Market Leaders

• Table 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
• Table 3.2 Global Market Share (%) and Revenue ($m) by Country/Region, 2007
• Table 3.3 Big Pharma' s Biotech Revenue ($m), 2007
• Table 3.4 Top-10 Biotech Companies ($m), 2007
• Table 4.1 Biotech Market SWOT Analysis
• Table 4.2 Biotech Market Capitalisation ($bn) over 10-Year Period, 1997-2007
• Table 4.3 Patent Expiration of Leading Biotech Drugs
• Table 5.1 Top-10 Biotech Companies Revenues ($m) Forecast, 2008-2023
• Table 6.1 Amgen Revenues and Net Income ($m), 2003-2007
• Table 6.2 Amgen: Total Corporate Revenues ($m), 2008-2023
• Table 6.3 Amgen Leading Drug Sales ($m), 2007
• Table 6.4 Amgen' s Geographical Sales ($m), 2007
• Table 6.5 Amgen' s Top-Three Drugs - Sales ($m) Forecast, 2008-2013
• Table 6.6 Amgen' s Phase III Pipeline, 2008
• Table 7.1 Genentech Revenues and Net Income ($m), 2003-2007
• Table 7.2 Genentech: Total Corporate Revenues ($m), 2008-2023
• Table 7.3 Genentech' s Leading Drugs ($m), 2007
• Table 7.4 Genentech' s Geographical Sales ($m), 2007
• Table 7.5 Genentech' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 7.6 Genentech' s Phase III Pipeline, 2008
• Table 8.1 UCB Revenues and Net Profit ($m), 2003-2007
• Table 8.2 UCB: Total Corporate Revenues ($m), 2008-2023
• Table 8.3 UCB' s Leading Drugs ($m), 2007
• Table 8.4 UCB' s Geographical Sales ($m), 2007
• Table 8.5 UCB' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 8.6 UCB' s Phase III Pipeline, 2008
• Table 9.1 Gilead Sciences Revenues ($m), 2003-2007
• Table 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
• Table 9.3 Gilead Sciences' Leading Drugs Sales ($m), 2006-2007
• Table 9.4 Gilead Sciences' Geographical Sales ($m), 2007
• Table 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 9.6 Gilead Sciences' Phase III Pipeline, 2008
• Table 10.1Genzyme Revenues ($m), 2003-2007
• Table 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
• Table 10.3 Genzyme' s Leading Products ($m), 2006-2007
• Table 10.4 Genzyme' s Geographical Sales ($m), 2006
• Table 10.5 Genzyme' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 10.6 Genzyme' s Phase III Pipeline, 2008
• Table 11.1 Biogen Idec Revenues ($m), 2003-2007
• Table 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
• Table 11.3 Biogen Idec' s Leading Drugs ($m), 2006-2007
• Table 11.4 Biogen Idec' s Geographical Sales ($m), 2006-2007
• Table 11.5 Biogen Idec' s Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 11.6 Biogen Idec' s Phase III Pipeline, 2008
• Table 12.1 CSL Revenues and Net Profit ($m), 2003-2007
• Table 12.2 CSL: Total Corporate Revenues ($m), 2008-2023
• Table 12.3 CSL' s Leading Drugs ($m), 2006-2007
• Table 12.4 CSL' s Geographical Sales ($m), 2007
• Table 12.5 CSL' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 12.6 CSL' s Phase III Pipeline, 2008
• Table 13.1 Cephalon' s Revenues ($m), 2003-2007
• Table 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
• Table 13.3 Cephalon' s Leading Drugs ($m), 2006-2007
• Table 13.4 Cephalon' s Geographical Sales ($m), 2007
• Table 13.5 Cephalon' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 13.6 Cephalon' s Phase III Pipeline, 2008
• Table 14.1 Celgene' s Revenues ($m), 2003-2007
• Table 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
• Table 14.3 Celgene' s Leading Drugs ($m), 2006-2007
• Table 14.4 Celgene' s Geographical Sales ($m), 2006-2007
• Table 14.5 Celgene' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 14.6 Celgene' s Phase III Pipeline, 2008
• Table 15.1 Actelion Revenues and Net Profit ($m), 2003-2007
• Table 15.2 Actelion: Total Corporate Revenues ($m), 2008-2023
• Table 15.3 Actelion' s Leading Drugs ($m), 2006-2007
• Table 15.4 Actelion' s Geographical Sales ($m), 2006-2007
• Table 15.5 Actelion' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Table 15.6 Actelion' s Phase III Pipeline, 2008

• Figure 3.1 Global Biotech Market Revenues ($m) Forecast 2008-2023
• Figure 3.2 Global Biotech Market Share (%), 2007
• Figure 3.3 Big Pharma Biotech Market Share (%), 2007
• Figure 3.4 Top-10 Biotech Companies Market Share (%), 2007
• Figure 4.1 Biotech Market Capitalisation ($bn) over 10-Year Period 1997-2007
• Figure 5.1 Top-10 Biotech Market Revenues ($m) Forecast, 2008-2023
• Figure 6.1 Amgen Revenues ($m), 2003-2007
• Figure 6.2 Amgen Net Income ($m), 2003-2007
• Figure 6.3 Amgen: Total Corporate Revenues ($m), 2008-2023
• Figure 6.4 Amgen' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 6.5 Amgen' s Geographical Sales (%), 2007
• Figure 6.6 Amgen' s Top-Three Drugs  Total Sales ($m) Forecast, 2008-2013
• Figure 7.1 Genentech Revenues ($m), 2003-2007
• Figure 7.2 Genentech Net Income ($m), 2003-2007
• Figure 7.3 Genentech: Total Corporate Revenues ($m), 2008-2023
• Figure 7.4 Genentech' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 7.5 Genentech' s Geographical Sales (%), 2007
• Figure 7.6 Genentech' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 8.1 UCB Revenues ($m), 2003-2007
• Figure 8.2 UCB Net Profit ($m), 2003-2007
• Figure 8.3 UCB: Total Corporate Revenues ($m), 2008-2023
• Figure 8.4 UCB' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 8.5 UCB' s Geographical Sales (%), 2007
• Figure 8.6 UCB' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 9.1 Gilead Sciences Revenues ($m), 2003-2007
• Figure 9.2 Gilead Sciences: Total Corporate Revenues ($m), 2008-2023
• Figure 9.3 Gilead Sciences' Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 9.4 Gilead Sciences' Geographical Sales (%), 2007
• Figure 9.5 Gilead Sciences' Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 10.1 Genzyme Revenues ($m), 2003-2007
• Figure 10.2 Genzyme: Total Corporate Revenues ($m), 2008-2023
• Figure 10.3 Genzyme' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 10.4 Genzyme Geographical Sales (%), 2006
• Figure 10.5 Genzyme' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 11.1 Biogen Idec Revenues ($m), 2003-2007
• Figure 11.2 Biogen Idec: Total Corporate Revenues ($m), 2008-2023
• Figure 11.3 Biogen Idec' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 11.4 Biogen Idec' s Geographical Sales (%), 2007
• Figure 11.5 Biogen Idec' s Top-Two Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 12.1 CSL Revenues ($m), 2003-2007
• Figure 12.2 CSL Net Profit ($m), 2003-2007
• Figure 12.3 CSL: Total Corporate Revenues ($m), 2008-2023
• Figure 12.4 CSL' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 12.5 CSL' s Geographical Sales (%), 2007
• Figure 12.6 CSL' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 13.1 Cephalon' s Revenues ($m), 2003-2007
• Figure 13.2 Cephalon: Total Corporate Revenues ($m), 2008-2023
• Figure 13.3 Cephalon' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 13.4 Cephalon' s Geographical Sales (%), 2007
• Figure 13.5 Cephalon' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 14.1 Celgene' s Revenues ($m), 2003-2007
• Figure 14.2 Celgene: Total Corporate Revenues ($m), 2008-2023
• Figure 14.3 Celgene' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 14.4 Celgene' s Geographical Sales (%), 2007
• Figure 14.5 Celgene' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013
• Figure 15.1 Actelion Revenues ($m), 2003-2007
• Figure 15.2 Actelion Net Profit ($m), 2003-2007
• Figure 15.3 Actelion: Total Corporate Revenues ($m), 2008-2023
• Figure 15.4 Actelion' s Leading Drugs: Contribution to Company Sales (%), 2007
• Figure 15.5 Actelion' s Geographical Sales (%), 2007
• Figure 15.6 Actelion' s Top-Three Drugs - Total Sales ($m) Forecast, 2008-2013

Companies mentioned in report:

• Abbott
• Abgenix
• Actelion
• Amgen
• Anthrogenesis
• AstraZeneca
• Biogen Idec
• Bristol-Myers Squibb
• Cardiokine Biopharm
• Celera Genomics
• Celgene
• Cephalon
• Chugai
• CoTherix
• CSL Ltd
• CuraGen
• Eisai
• Eli Lilly
• EMEA
• FDA
• Genentech
• Genzyme
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Human Genome Sciences
• Immunex-
• Incyte Genomics
• Iomai Corporation
• Johnson & Johnson (J&J)
• MedImmune
• Merck KGaA
• MGI
• Millennium Pharmaceuticals
• Mundipharma
• Myriad Genetics
• Novartis
• Novo Nordisk
• Pfizer
• Pharmion
• Roche
• Roche Centre for Medical Genomics (RCMG)
• Sanofi-Aventis
• Schering-Plough
• Schwarz Pharma
• Serono (now Merck Serono)
• Signal Pharmaceuticals
• Teva
• UCB
• US Congressional Budget Office (CBO)
• Ventana Medical Systems
• World Health Organisation (WHO)
• Wyeth
• Zenyaku